<DOC>
	<DOCNO>NCT02840110</DOCNO>
	<brief_summary>Subjects treat ACTR087 may participate long-term follow-up study completion final schedule visit parent clinical study investigational setting , compassionate use , name patient IND , expand access program , equivalent setting . No investigational product treatment administer study . These subject follow safety monitoring schedule decrease frequency 15 year post-ACTR087 treatment , accordance US FDA Regulatory guidance pertain long-term safety follow-up study subject receive recombinant DNA-containing investigational product .</brief_summary>
	<brief_title>Long-Term Follow-Up Study Clinical Study Subjects Treated With ACTR087</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Willing provide inform consent participation study Treated ACTR087 investigational setting If treat ACTR087 interventional clinical study , complete study assessment followup visit parent study extent willing able If treat ACTR087 investigational setting , compassionate use , name patient IND , expand access program , equivalent setting , complete assessment follow visit set extent willing able Able comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>